WO1999015636A1 - Expression of starch-binding domain (sbd) - Google Patents
Expression of starch-binding domain (sbd) Download PDFInfo
- Publication number
- WO1999015636A1 WO1999015636A1 PCT/DK1998/000411 DK9800411W WO9915636A1 WO 1999015636 A1 WO1999015636 A1 WO 1999015636A1 DK 9800411 W DK9800411 W DK 9800411W WO 9915636 A1 WO9915636 A1 WO 9915636A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bacillus
- starch
- host cell
- sbd
- host
- Prior art date
Links
- 229920002472 Starch Polymers 0.000 title claims abstract description 50
- 239000008107 starch Substances 0.000 title claims abstract description 50
- 235000019698 starch Nutrition 0.000 title claims abstract description 50
- 230000014509 gene expression Effects 0.000 title claims abstract description 34
- 108010061330 glucan 1,4-alpha-maltohydrolase Proteins 0.000 claims abstract description 26
- 108090000623 proteins and genes Proteins 0.000 claims description 52
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 38
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 36
- 239000013598 vector Substances 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 27
- 241000193385 Geobacillus stearothermophilus Species 0.000 claims description 22
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 22
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 22
- 229920001184 polypeptide Polymers 0.000 claims description 20
- 230000001105 regulatory effect Effects 0.000 claims description 16
- 239000013612 plasmid Substances 0.000 claims description 13
- 239000013604 expression vector Substances 0.000 claims description 11
- 239000006228 supernatant Substances 0.000 claims description 11
- 230000002103 transcriptional effect Effects 0.000 claims description 9
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 7
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims description 7
- 239000005090 green fluorescent protein Substances 0.000 claims description 7
- 235000015097 nutrients Nutrition 0.000 claims description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 5
- 241000233866 Fungi Species 0.000 claims description 5
- 230000002255 enzymatic effect Effects 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000003550 marker Substances 0.000 claims description 5
- 241000194110 Bacillus sp. (in: Bacteria) Species 0.000 claims description 4
- 238000012544 monitoring process Methods 0.000 claims description 4
- 230000014621 translational initiation Effects 0.000 claims description 4
- 241000228212 Aspergillus Species 0.000 claims description 3
- 241000194108 Bacillus licheniformis Species 0.000 claims description 3
- 239000013613 expression plasmid Substances 0.000 claims description 3
- 238000005457 optimization Methods 0.000 claims description 3
- 241000193744 Bacillus amyloliquefaciens Species 0.000 claims description 2
- 241000194107 Bacillus megaterium Species 0.000 claims description 2
- 244000005700 microbiome Species 0.000 claims description 2
- 241000894007 species Species 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 abstract description 10
- 108090000790 Enzymes Proteins 0.000 abstract description 10
- 229940088598 enzyme Drugs 0.000 abstract description 10
- 238000010276 construction Methods 0.000 abstract description 5
- 210000004027 cell Anatomy 0.000 description 33
- 102000004169 proteins and genes Human genes 0.000 description 31
- 235000018102 proteins Nutrition 0.000 description 29
- 239000012634 fragment Substances 0.000 description 14
- 108010025880 Cyclomaltodextrin glucanotransferase Proteins 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 12
- 235000014469 Bacillus subtilis Nutrition 0.000 description 9
- 241000588724 Escherichia coli Species 0.000 description 9
- 244000063299 Bacillus subtilis Species 0.000 description 8
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 7
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 7
- 108010076504 Protein Sorting Signals Proteins 0.000 description 6
- 230000003248 secreting effect Effects 0.000 description 6
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 230000003197 catalytic effect Effects 0.000 description 5
- 229930027917 kanamycin Natural products 0.000 description 5
- 229960000318 kanamycin Drugs 0.000 description 5
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 5
- 229930182823 kanamycin A Natural products 0.000 description 5
- 241000193752 Bacillus circulans Species 0.000 description 4
- 102100022624 Glucoamylase Human genes 0.000 description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000001632 sodium acetate Substances 0.000 description 4
- 235000017281 sodium acetate Nutrition 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 101100001650 Geobacillus stearothermophilus amyM gene Proteins 0.000 description 3
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- 241000228245 Aspergillus niger Species 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 101710089384 Extracellular protease Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- -1 AmyL Chemical class 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 241001513093 Aspergillus awamori Species 0.000 description 1
- 240000006439 Aspergillus oryzae Species 0.000 description 1
- 108090000145 Bacillolysin Proteins 0.000 description 1
- 101000775727 Bacillus amyloliquefaciens Alpha-amylase Proteins 0.000 description 1
- 108010029675 Bacillus licheniformis alpha-amylase Proteins 0.000 description 1
- 241000194103 Bacillus pumilus Species 0.000 description 1
- 108091005658 Basic proteases Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241001137251 Corvidae Species 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 101710106383 Disulfide bond formation protein B Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 101710194570 Glucoamylase I Proteins 0.000 description 1
- 108050008938 Glucoamylases Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000178960 Paenibacillus macerans Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 101710116318 Probable disulfide formation protein Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 238000006959 Williamson synthesis reaction Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 1
- 101150098274 amyM gene Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 235000015108 pies Nutrition 0.000 description 1
- 238000013492 plasmid preparation Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 108091009163 starch binding proteins Proteins 0.000 description 1
- 102000025928 starch binding proteins Human genes 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
- C12N9/2411—Amylases
- C12N9/2414—Alpha-amylase (3.2.1.1.)
- C12N9/2417—Alpha-amylase (3.2.1.1.) from microbiological source
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- the present invention relates to a DNA construct encoding a starch-binding domain being a region in the maltogenic amylase enzyme product produced by Bacillus stearoth ⁇ rmophilus C599 disclosed in EP patent no. 120,693 (Novo Industri A/S), the starch-binding domain itself, an expression vector comprising the starch-binding domain of the invention, a host cell transformed with said expression vector of the invention, a method for expressing the starch-binding domain of the invention in a Bacillus sp. host strain transformed with the expression vector of the invention.
- EP patent no. 120,693 discloses a maltogenic amylase derived from Bacillus stearothermophilus C599.
- SBD Starch Binding Domain
- CGTases i.e. cyclodextrin glucanotransferases (E.C. 2.4.1.19), and glucoamylases (E.C. 3.2.1.3). See also Chen et al. (1991), Gene 991, p. 121-126, describing Starch Binding Domain hybrids.
- a SBD has been found in the commercially available enzyme AMGTM (a glucoamylase) from Aspergillus niger (Belshaw et al. (1993), "Specificity of the binding doamin of glycoamylase I" Eur. J. Biochem, 211:717-724). Furthermore, a SBD from a CGTase derived from Bacillus macerans has also been described. Dalmia et al. (1995), Biothech. Bioeng., Vol 47, pp. 576-584 describes expression of the starch-binding domain (E-domain) of glucoamylase I from Aspergillus awamori and of a CGTase from Ba cillus macerans in E. coli .
- AMGTM a glucoamylase
- E. coli expression results in intracellular none-soluble protein aggregate (i.e. inclusion bodies).
- single SBD may also be referred to as “isolated SBD” or “separate SBD”.
- a "single SBD” includes up to the entire part of the amino acid sequence of a SBD- containing enzyme, e . g. a polysaccharide hydrolyzing enzyme, being essentially free of the catalytic domain, but retaining the SBD unit (s) .
- the entire catalytic amino acid sequence of a starch degrading enzyme e.g. a glu- coamylase
- other enzymes comprising one or more SBD units is not to be regarded as a single SBD.
- a single SBD constitutes one or more SBD units of a polysaccharide hydrolyzing enzyme, one or more SBD units of a starch binding protein or a protein designed and/or engineered to be capable of binding to starch.
- the single SBD is at least as large as the minimum number of amino acids in the amino acid sequence required to bind to starch.
- a single SBD may also be an amino acid sequence, in which the binding and catalytic domain are one and the same.
- Isolation of a starch-binding domain In order to isolate the starch-binding domain of e.g. a glucoamylase, several genetic approaches may be used.
- One method uses restriction enzymes to remove a portion of the gene and then to fuse the remaining gene-vector fragment in frame to obtain a mutated gene that encodes a protein truncated for a particular gene fragment.
- Another method involves the use of exonucleases such as Bal31 to systematically delete nucleotides either externally from the 5' and the 3' ends of the DNA or internally from a restricted gap within the gene. These gene deletion methods result in a mutated gene encoding a shortened gene molecule which may then be evaluated for starch binding ability.
- a DNA sequence encoding the starch binding domain may then be manipulated in a variety of ways to fuse it to a DNA sequence encoding an enzyme of interest.
- the starch-binding domain encoding fragment and the DNA encoding the enzyme of interest are then ligated with or without a linker.
- the resulting ligated DNA may then be manipulated in a variety of ways to provide for expression.
- Microbial hosts such as Aspergillus, e . g. , A. niger and A. oryzae, Bacillus, E. coli or S . cerevisiae are preferred.
- the invention relates to an isolated DNA sequence comprising a DNA sequence encoding the E-domain (SEQ ID NO: 2) of the maltogenic amylase produced by Bacillus stea- rothermophilus C599, without having the enzymatic activity of the maltogenic amylase produced by Bacillus stearothermophilus C599.
- the Bacillus stearothermophilus C599 is described in EP 120,693.
- the invention relates to a single SBD polypeptide encoded by a DNA sequence of the invention encoding a SBD of the invention, in particular the ones shown in SEQ ID NO: 2 (E domain) or SEQ ID NO: 4 (D+E domain) .
- the invention relates to a Bacillus host transformed with a vector comprising a DNA sequence coding for a starch-binding domain of the invention and which is capable of expressing said sequence.
- the invention relates to a Bacillus expression vector which carries an inserted DNA sequence encoding for a starch-binding domain, in particular an isolated DNA sequence of the invention as described above.
- the invention relates to a method of producing a single starch-binding domain polypeptide in a Bacillus host cell, the method comprising the steps of:
- Bacillus host cell which has been transformed with an expression cassette which includes, as operably joined components: a) a transcriptional and translational initiation regulatory region, b) a DNA sequence encoding the starch-binding domain polypeptide, C) a transcriptional and translational termination regulatory region, wherein the regulatory regions are functional in the host, and d) a selection marker gene for selecting transformed host cells; and
- the invention also relates to a method for optimization of SBD expression in a Bacillus host, the method comprising the steps of: a. expression in the host of a SBD fused to a reporter molecule; b. monitoring the concentration of expressed SBD in the supernatant of the fermented host by measuring the intrinsic property or properties of the reporter molecule.
- the invention relates to a method of producing a hybrid, wherein the hybrid is expressed in a Bacillus host, growing the transformed host under conditions whereby the transformed culture is substantially free of un-transformed cells; incubating the transformed culture in a nutrient medium, whereby the hybrid is overproduced; and recovering the hybrid.
- Figure 1 shows the sequence alignment (of the D and E-domain) of the maltogenic amylase from B . stearothermophilus C599 and B . circulans strain 251 CGTase.
- Bold are residues in ⁇ volved in maltose binding via their side-chain and written in " Italic” are residues with side-chains involved in maltose binding in MBS 2.
- Figure 2 shows the SDS-PAGE gel of the purified E-domain single SBD: Lane 1 and 3: Molecular weight standards (from above): 94, 67, 43, 30, 20, 14 kDa; lane 2: single SBD (E-domain).
- the inventors of the present invention found by alignment of the amino acid sequence (in the D and E domains) of the Bacillus stearothermophilus C599 maltogenic amylase that it had a high identity to CGTases, in particular to a Bacillus circulans strain 251 CGTase (Lawson, C.L., Montfort, R.v., Strokopytov, B., Rozeboom, H.J., Kalk, K.H., Vries, G.E.d., Penninga, D. , Dijkhuizen, L. and Dijkstra, B. 1994; J. Mol. Biol. 236, p.590- 600) .
- the identity for the E-domains was found to be 48% and the identity for the D-E-domains 45% using the "align" program based on the Smith-Waterman method and BLOSUM45 table (Henikoff S, Henikoff JG, 1992, Proc. Natl. Acad. Sci. USA89: 10915-10919) .
- the structure of the B . circulans strain 251 CGTase in complex with maltose was published by Lawson C.L. et al. (1994), supra) and can be found in Brookhaven data-bank under the code lCDG.pdb.
- the CGTase structure consists of five domains of which the A, B and C domains are similar to the domains found in ⁇ -amylases. The additional domains named D and E, respectively, are unique for CGTases.
- maltose binding site 1 MBS 1
- MBS 2 maltose binding site 2
- W616 and W662 are stacking with the glucose rings and the side-chains of K651 and N667 are forming hydrogen bonds to -OH groups at the glucose rings in MBS 1.
- the MBS 2 is defined by stacking with Y633 and H-bonds to the side-chain of residue T598, N603, N627 and Q628. Also in the maltogenic a y- lase the positions T598, Q628 and Y633 are present, whereas the N603 position is substituted by K (Lys) which is also potential to form H-bond to -OH groups. No analogue to N627 is present. Based on the alignment and the present of the residues analogue to MBS defining residues in the CGTase it is most likely that the maltose binding sites are also found in the maltogenic amylase.
- the high homology between the CGTase and the maltogenic amylase indicates the same overall structure, and the structure of the CGTase can therefore be used for determining the different domains in the maltogenic amylase.
- the starting point of the D-domain was determined to amino residue 494 and the E-domain determined to start with amino residue 576.
- the theoretical sizes of D-E and E-domains are therefore 193 amino acids and 111 amino acids respectively, corresponding to 20 kDa and 12 kDa.
- the maltogenic amylase product produced by Bacillus stearothermophilus C599 disclosed in EP patent no. 120,693 comprises a SBD in the C-terminal part of the protein sequence.
- the invention relates to an isolated DNA sequence comprising a DNA sequence encoding the E domain of the maltogenic amylase produced by Bacillus stearothermophilus C599 without having the enzymatic activity of the maltogenic amylase produced by Bacillus stearothermophilus C599.
- the E domain coding DNA sequence is the sequence shown in SEQ ID NO: 1.
- the corresponding protein sequence is shown in SEQ ID NO: 2.
- the isolated DNA sequence of the invention further comprising the D-domain of the maltogenic amylase produced by Bacillus stearothermophilus C599 without having the enzymatic activity of the maltogenic amylase produced by Bacillus stearothermophilus C599.
- the isolated DNA se- quence contains the DE-domain coding DNA sequence.
- the DE-domain coding sequence is shown in SEQ ID NO: 3.
- the DE domain protein sequence is shown in SEQ ID NO: 4.
- the invention relates to a single SBD with starch-binding affinity encoded by the above-mentioned iso ⁇ lated DNA sequences of the invention.
- SBD with starch-binding affinity is shown in SEQ ID NO: 2 (E-domain) and SEQ ID NO: 4 (DE-domain) .
- Example 1 describes the construction of an expression vector and expression of the single SDB from the maltogenic amylase from Bacillus stearothermophilus C599 in a Bacillus host . Further, in the third aspect the invention relates to a method of producing a single starch-binding domain polypeptide in a Bacillus host cell, the method comprising the steps of:
- a Bacillus host cell which has been transformed with an expression cassette which includes, as op- erably joined components: a) a transcriptional and translational initiation regulatory region, b) a DNA sequence encoding the starch-binding domain polypep- tide, c) a transcriptional and translational termination regulatory region, wherein the regulatory regions are functional in the host, and d) a selection marker gene for selecting transformed host cells; and
- E . coli has a periplasmic space where proper folding of heterologues expressed genes is possible (for review see for example Hockney, R.C. (1994) TIBTECH, vol.12, p. 56-463). Especially the oxidiz- ing potential and the existence of disulfide oxidoreductases in the periplasma are necessary when expressing proteins with a functionality dependent on properly arranged disulfide bridges (Emmanuel Brun et al. (1995) .
- the periplasma of E. coli also acts in protecting the heterelogously expressed protein towards the action of proteases present in the supernatant as well as the cytoplasm. It is also known that when expressing secreted proteins with disulfide bridges in Bacillus subtilis the level of expression drops significantly (Bertus van den Berg et al., (1993), Introduction of disulfide bonds into Bacillus subtilis neutral protease. Protein Engineering, vol.6 no.5, p. 521-527).
- Bacillus subtilis is known to express at least 7 different extracellular proteases (Eds. A.L. Sonenshein, J.A. Hoch and Richard Losick (1993) Bacillus subtilis and other Gram-Positive Bacteria, American Society for microbiology, p.939).
- the present invention relates to a Bacil- lus host cell transformed with a vector comprising a DNA sequence coding for a SBD and capable of expressing the sequence.
- the expressed single SBD or SBD- containing polypeptide has a molecular weight (M w ) which is equal to or higher than about 4 kD.
- M w is equal to or below about 35 kD, more preferably about 32 kD, even more preferably about 30 kD, especially about 25 kD.
- the D-domain of Bacillus stearothermophi lus C599 has a M w around 12 kD and the DE-domain a M w around 20 kD.
- the SBD may be expressed in the form of a single SBD as de- fined above, i . e . , a polypeptide comprising one SBD.
- the SBD may be expressed in the form of a dimer or trimer or even a polymer, i . e . a polypeptide or protein comprising two, three, or even more than three identical SBD "units".
- the SBD can also be expressed as a part of a multi-domain polypeptide, the non-SBD part of such a polypeptide being for example one, two or even more domains without catalytic activity.
- SBDs can be expressed according to the present invention, i.e. by means of a transformed Bacillus host.
- SBDs obtainable from a microorganism or a plant, more preferably from a bacterium or from a fungus, are expressed.
- SBDs from bacteria and fungus examples include SBDs obtainable from species mentioned above in the "Background" sec- tion, in particular the ones belonging to bacteria genus Bacil ⁇ lus and the fungus genus Aspergillus .
- the Bacillus host cell of the invention is a neutralo- philic or an alkalophilic or a mesophilic or a thermophilic host cell.
- EX Examples of hosts which are useful in the context of the present invention are hosts from the species Bacillus subtilis , Bacillus licheniformis, Bacillus megaterium, Bacillus stea- rothermophilos , and Bacillus amyloliquefaciens . However, it is contemplated that other Bacillus species may also be useful hosts for expression of SBDs.
- the host cell of the invention is transformed with a vector comprising a SBD encoding DNA sequence.
- the vector is integrated into the genome of the host, more preferably it has been amplified on the genome .
- the vector is present as an expression plasmid, preferably as a multi- copy plasmid.
- the present invention relates to a Bacillus expression vector which carries an inserted SBD-encoding DNA sequence.
- the expression cassette of the vector comprises regulatory regions from a Bacillus sp. , more preferably are such regulatory regions endogenous to the host.
- the present invention relates to a method for producing a SBD polypeptide, the method comprising the steps of:
- Bacillus host cells which have been transformed with an expression cassette which includes, as op- erably joined components, a) a transcriptional and translational initiation regulatory region, b) a DNA sequence encoding the starch-binding domain polypeptide, c) a transcriptional and translational termination regulatory region, wherein the regulatory regions are functional in the host, and d) a selection marker gene for selecting transformed host cell; and
- the present invention relates to a method for optimization of SBD expression in a Bacillus host, the method comprising the steps of expression in the host of a SBD fused to a reporter molecule; and monitoring the concentration of expressed SBD in the supernatant of the fermented host by measuring the intrinsic property or properties of the reporter molecule.
- the reporter molecule is a Green Fluorescent Protein
- the intrinsic property is fluorescence emission
- the invention relates to a polypeptide hybrid consisting essentially of one or more starch- binding domain (s) fused to a green fluorescent protein, and to a method of producing such a hybrid by expression in a Bacillus host, growth of the transformed host under conditions whereby the transformed culture is substantially free of untransformed cells; incubation of the transformed culture in a nutrient medium, whereby the hybrid is overproduced; and recovery of the hybrid.
- a polypeptide hybrid consisting essentially of one or more starch- binding domain (s) fused to a green fluorescent protein
- a recombinant vector comprising a DNA construct encoding the single SBD of the invention may be any vector which conveniently may be subjected to recombinant DNA procedures, and the choice of vector will often depend on the host cell, into which it is to be introduced.
- This introduction of vector into the host cell is often referred to as the transformation of the host cell.
- transformation indicates introduction of DNA into a host cell by using, e.g. protoplasts, natural competent cells, transfection, conjugation, electroporation, or any equivalent method.
- the vector may be an autonomously replicating vector, i.e. a vector which exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g. a plasmid.
- the vector may be one which, when introduced into a host cell, is integrated into the host cell genome in part or in its entirety and replicated together with the chromosome (s) , into which it has been integrated.
- the vector is preferably an expression vector in which the DNA sequence encoding the single SBD of the invention is operably linked to additional segments required for transcription of the DNA.
- the expression vector is derived from plasmid or viral DNA, or may contain elements of both.
- operably linked indicates that the segments are arranged so that they function in concert for their intended purposes, e.g. transcription initiates in a promoter and proceeds through the DNA sequence coding for the SBD.
- the promoter may be any DNA sequence which shows transcriptional activity in the host cell of choice and may be derived from genes encoding proteins either homologous or heterologous to the host cell.
- suitable promoters for use in bacterial host cells include the promoter of the Bacillus stearothermophilus maltogenic amylase gene, the Bacillus licheniformis -amylase gene, the Bacillus amyloliquefaciens ⁇ -amylase gene, the Bacillus subtilis alkaline protease gene, or the Bacillus pumilus xylosidase gene, or the phage Lambda P R or P L promoters or the E. coli lac, trp or tac promoters.
- the DNA sequence encoding the SBD of the invention may also, if necessary, be operably connected to a suitable terminator.
- the recombinant vector of the invention may further comprise a DNA sequence enabling the vector to replicate in the host cell in question.
- the vector may also comprise a selectable marker, e.g. a gene the product of which complements a defect in the host cell, or a gene encoding resistance to e.g. antibiotics like kanamycin, chloramphenicol, erythromycin, tetracycline, spectinomycine, or the like, or resistance to heavy metals or herbicides.
- a selectable marker e.g. a gene the product of which complements a defect in the host cell, or a gene encoding resistance to e.g. antibiotics like kanamycin, chloramphenicol, erythromycin, tetracycline, spectinomycine, or the like, or resistance to heavy metals or herbicides.
- a secretory signal sequence (also known as a leader sequence, prepro sequence or pre sequence) may be provided in the recombinant vector.
- the secretory signal sequence is joined to the DNA sequence encoding the SBD in the correct reading frame.
- Secretory signal sequences are commonly positioned 5' to the DNA sequence encoding the.
- the secretory signal sequence may be that normally associated with the SBD or may be from a gene encoding another secreted protein.
- Green Fluorescent Protein has become a widely used reporter molecule for monitoring gene expression, tracers of cell lineage and as fusion tags for proteins.
- GFP Green Fluorescent Protein
- GFP could be fused to SBD' s creating a fusion protein having the starch-binding property as well as the fluorescent properties.
- the expression of this fusion protein could be used to monitor the expressing of SBD' s in Bacillus species and hereby be used to optimize expression levels of given SBD's.
- Bacillus stearothermophilus C599 (EP 120,683) comprises the maltogenic amylase.
- Plasmids P.L. J ⁇ rgensen, C.K.Hansen, G.B.Poulsen and B. Diderichsen, (1990), In vivo genetic engineering: homologues recombination as a tool for plasmid construction, Gene, 96, p. 37- 41.)
- Oligonucleotide PCR primers were designed to express the E- domain alone and the D+E domain part of the AmyM protein (i.e. maltogenic amylase of Bacillus stearothermophilus C599) .
- the ra- tionale was to add the signal sequence of the Bacillus licheni - formis ⁇ -amylase (AmyL, TermamylTM, see P.L. J ⁇ rgensen et al. (1990), Gene, 96, p. 37-41) in front of these AmyM fragments in attempts to have the proteins secreted from Bacillus .
- the following primers were used: #110755:
- Template for the PCR reaction was a sample of plasmid pDN1413. This is essentially plasmid pUBllO containing the amyM gene fragment, derived from the deposited strain NCIB 11837 via plasmid pDN452 which is described in EP 120,693.
- Conditions for the PCR amplification were the following: 94°C for 2 minutes, then 20 cycles of 49°C for 30 seconds, 43°C for 1 minute, 72°C for 2 minutes, then one cycle of 72°C for 5 minutes.
- Primer #110755 together with #110757 resulted in a 820 basepair fragment
- primer #110756 together with #110757 resulted in a 571 basepair fragment.
- PCR fragments were purified using a QIAquick PCR Purification Kit Cat. No. 28106 from Qiagen, and digested with EcoRI + Pstl. Plasmid pDN1981 (P.L. J ⁇ rgensen et al. (1990), Gene, 96, p. 37-41) was used as cloning vector. pDN 1981 was digested with EcoRI + Pstl, and the 3.9 kb fragment purified from an agarose gel. The vector fragment was ligated with each of the digested PCR fragments, and the ligation mixtures transformed into compe- tent cells of Bacillus subtilis DN1885 (Diderichsen et al.,
- Strains SJ4302-SJ4305 were inoculated in 10 ml TY broth containing 0.4% glucose and lO ⁇ g/ml kanamycin, and incubated at 37°C with shaking for two days.
- Strain DN1885 (the B . subtilis host strain) was inoculated in 10 ml TY broth with 0.4% glucose, and incubated at 37°C with shaking for two days.
- SJ4302 and SJ4303 may be due to these clones harboring PCR amplified constructs, that were not veri- fied by DNA sequencing - an error might thus have been introduced into the SJ4303 clone.
- PSJ4305 E-domain clone was transformed into competent cells of B . subtilis ToC46 (Diderichsen et al., Journal of Bacteriology, vol. 172, p. 4315-4321, 1990), selecting kanamycin resistance (10 mg/ml) , and a transformant was kept as SJ4547.
- the supernatant was centrifuged (4500 rpm, 15 min, 8°C) using a Sorvall RC-3B centrifuge, equipped with a 4600 A rotor head, followed by subsequent filtration through a 0.7 mm glass mi- crofibre filter.
- the supernatant was applied to ⁇ -cyclodextrin- agarose (1.6 x 5 cm) in 25 mM sodium acetate, 1 mM CaCl 2 , 0.5 M NaCl, pH 5.0, at a flow rate of 300 ml h "1 .
- the column was washed (10 column volumes) using 25 mM sodium acetate, 1 mM CaCl 2 , 0.5 M NaCl, pH 5.0, and the single SBD was eluted in the same buffer containing 2% (w/v) ⁇ -cyclodextrin.
- the eluted SBD was pooled and dialyzed against 50 mM sodium acetate, 1 mM CaCl 2 , pH 5.0.
- the purified single SBD was homogeneous as determined using SDS- PAGE (see below) . N-terminal sequencing showed SGTQTSVVF and confirmed that the purified E-domain is identical to residue
- Starch binding of single SBD Adsorption of single SBD onto granular starch is determined by incubating increasing amounts of SBD (0-3 mg/ml) with granular corn starch (10 mg/ml) in 5 mM sodium acetate, pH 3.6 at 4°C for 16 hours, essentially as described (Belshaw & Wil- liamson, 1990) . The reaction is terminated by centrifugation and the protein concentration in the supernatant is subsequently determined and subtracted from the total protein to give the amount of starch bound protein.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU92541/98A AU9254198A (en) | 1997-09-24 | 1998-09-23 | Expression of starch-binding domain (sbd) |
EP98945082A EP1023438A1 (en) | 1997-09-24 | 1998-09-23 | Expression of starch-binding domain (sbd) |
JP2000512929A JP2003526314A (en) | 1997-09-24 | 1998-09-23 | Expression of starch binding domain (SBD) |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK110097 | 1997-09-24 | ||
DK1100/97 | 1997-09-24 | ||
US6155997P | 1997-10-07 | 1997-10-07 | |
US60/061,559 | 1997-10-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999015636A1 true WO1999015636A1 (en) | 1999-04-01 |
Family
ID=26065229
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DK1998/000411 WO1999015636A1 (en) | 1997-09-24 | 1998-09-23 | Expression of starch-binding domain (sbd) |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1023438A1 (en) |
JP (1) | JP2003526314A (en) |
AU (1) | AU9254198A (en) |
WO (1) | WO1999015636A1 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000077165A3 (en) * | 1999-06-11 | 2001-07-12 | Landbouwuniversiteit Wageninge | Expression in plants of starch binding domains and/or of protein fusions containing starch binding domains |
WO2005089102A2 (en) | 2004-02-04 | 2005-09-29 | Neose Technologies, Inc. | Methods of refolding mammalian glycosyltransferases |
WO2006092099A1 (en) * | 2005-03-03 | 2006-09-08 | Simpson Biotech Co. Ltd. | Recombinant protein comprising starch binding domain and use thereof |
WO2006108273A1 (en) | 2005-04-11 | 2006-10-19 | National Research Council Of Canada | Identification of a beta-1,3-n-acetylgalactosaminyltransferase (cgte) from campylobacter jejuni lio87 |
WO2007055789A3 (en) * | 2005-10-31 | 2007-10-25 | Neose Technologies Inc | Expression of soluble therapeutic proteins |
WO2007120932A2 (en) | 2006-04-19 | 2007-10-25 | Neose Technologies, Inc. | Expression of o-glycosylated therapeutic proteins in prokaryotic microorganisms |
WO2008052387A1 (en) * | 2006-10-31 | 2008-05-08 | Simpson Biotech Co., Ltd. | Starch binding domain and use thereof |
WO2008128345A1 (en) | 2007-04-20 | 2008-10-30 | National Research Council Of Canada | ENGINEERED VERSIONS OF CGTB (β-1,3- GALACTOSYLTRANSFERASE) ENZYMES, WITH ENHANCED ENZYMATIC PROPERTIES |
WO2008151448A1 (en) | 2007-06-15 | 2008-12-18 | National Research Council Of Canada | Engineered versions of polysialyltransferases with enhanced enzymatic properties |
CN102757501A (en) * | 2011-04-29 | 2012-10-31 | 中国科学院上海生命科学研究院 | Link application of protein tag |
US8784829B2 (en) | 2008-10-23 | 2014-07-22 | Intervet Inc. | Lawsonia intracellularis vaccines |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0120693A1 (en) * | 1983-03-25 | 1984-10-03 | Novo Nordisk A/S | Maltogenic amylase enzyme product, preparation and use thereof |
WO1998016190A1 (en) * | 1996-10-11 | 1998-04-23 | Novo Nordisk A/S | STARCH BINDING DOMAINS (SBDs) FOR ORAL CARE PRODUCTS |
-
1998
- 1998-09-23 EP EP98945082A patent/EP1023438A1/en not_active Withdrawn
- 1998-09-23 JP JP2000512929A patent/JP2003526314A/en active Pending
- 1998-09-23 WO PCT/DK1998/000411 patent/WO1999015636A1/en not_active Application Discontinuation
- 1998-09-23 AU AU92541/98A patent/AU9254198A/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0120693A1 (en) * | 1983-03-25 | 1984-10-03 | Novo Nordisk A/S | Maltogenic amylase enzyme product, preparation and use thereof |
WO1998016190A1 (en) * | 1996-10-11 | 1998-04-23 | Novo Nordisk A/S | STARCH BINDING DOMAINS (SBDs) FOR ORAL CARE PRODUCTS |
Non-Patent Citations (3)
Title |
---|
DATABASE MEDLINE, Accession No. 96-067699, LE GAL-COEFFET M.F. et al., "Expression in Aspergillus Niger of the Starch-Binding Domain of Glucoamylase. Comparison with the Proteolytically Produced Starch-Binding Domain"; & EUR. J. BIOCHEM., Vol. 233, Haefte 2, Oct. 1995, pages 561-567. * |
DATABASE MEDLINE, Accession no. 97-115811, PENNINGA D. et al., "The Raw Starch Binding Domain of Cyclodextrin Glycosyltransferase from Bacillus Circulans Strain 251"; & J. BIOL. CHEM., Vol. 271, Haefte 51, 20 Dec. 1996, pages 32777-32784. * |
PIR DATABASE, Accession No. S28784, DIDERICHSEN B. et al., "Cloning of a Maltogenic alpha-Amylase from Bacillus Stearothermophilus"; & FEMS MICROBIOL. LETT., 56, 1998, 30-60. * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7135619B1 (en) | 1999-06-11 | 2006-11-14 | Wageningen Universiteit | Expression in plants of starch binding domains and/or of protein-fusions containing starch binding domains |
WO2000077165A3 (en) * | 1999-06-11 | 2001-07-12 | Landbouwuniversiteit Wageninge | Expression in plants of starch binding domains and/or of protein fusions containing starch binding domains |
WO2005089102A2 (en) | 2004-02-04 | 2005-09-29 | Neose Technologies, Inc. | Methods of refolding mammalian glycosyltransferases |
EP2484759A2 (en) | 2004-02-04 | 2012-08-08 | BioGeneriX AG | Methods of refolding mammalian glycosyltransferases |
WO2006092099A1 (en) * | 2005-03-03 | 2006-09-08 | Simpson Biotech Co. Ltd. | Recombinant protein comprising starch binding domain and use thereof |
WO2006108273A1 (en) | 2005-04-11 | 2006-10-19 | National Research Council Of Canada | Identification of a beta-1,3-n-acetylgalactosaminyltransferase (cgte) from campylobacter jejuni lio87 |
US8043833B2 (en) | 2005-10-31 | 2011-10-25 | Novo Nordisk A/S | Expression of soluble therapeutic proteins |
WO2007055789A3 (en) * | 2005-10-31 | 2007-10-25 | Neose Technologies Inc | Expression of soluble therapeutic proteins |
WO2007120932A2 (en) | 2006-04-19 | 2007-10-25 | Neose Technologies, Inc. | Expression of o-glycosylated therapeutic proteins in prokaryotic microorganisms |
WO2008052387A1 (en) * | 2006-10-31 | 2008-05-08 | Simpson Biotech Co., Ltd. | Starch binding domain and use thereof |
WO2008128345A1 (en) | 2007-04-20 | 2008-10-30 | National Research Council Of Canada | ENGINEERED VERSIONS OF CGTB (β-1,3- GALACTOSYLTRANSFERASE) ENZYMES, WITH ENHANCED ENZYMATIC PROPERTIES |
WO2008151448A1 (en) | 2007-06-15 | 2008-12-18 | National Research Council Of Canada | Engineered versions of polysialyltransferases with enhanced enzymatic properties |
US8784829B2 (en) | 2008-10-23 | 2014-07-22 | Intervet Inc. | Lawsonia intracellularis vaccines |
CN102757501A (en) * | 2011-04-29 | 2012-10-31 | 中国科学院上海生命科学研究院 | Link application of protein tag |
Also Published As
Publication number | Publication date |
---|---|
JP2003526314A (en) | 2003-09-09 |
AU9254198A (en) | 1999-04-12 |
EP1023438A1 (en) | 2000-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3529774B2 (en) | Bacillus promoter derived from a mutant of the Bacillus liheniformis X-amylase promoter | |
KR102375732B1 (en) | Compositions and methods for increasing protein production in Bacillus licheniformis | |
CN100510095C (en) | Method for producing polypeptide in bacillocin cell | |
JP3220137B2 (en) | Alkaline protease and method for producing the same | |
CN103443278B (en) | The method for producing secreted polypeptides | |
EP2440573B1 (en) | Bacillus strain for increased protein production | |
DK1354056T3 (en) | IMPROVED secretion of a polypeptide by a microorganism | |
EP0941349B1 (en) | Methods for producing polypeptides in surfactin mutants of bacillus cells | |
US5958728A (en) | Methods for producing polypeptides in mutants of bacillus cells | |
JPH0829091B2 (en) | Method for producing hybrid PMA sequence and vector used in the method | |
LT4000B (en) | Expression module, transformed host cell, process for preparing serine protease, method of transformation, dna sequence, plasmid, oligonucleotide | |
CN112553134A (en) | Method for expressing alpha-amylase in bacillus subtilis | |
US5232841A (en) | Expression vectors containing a bacillus brevis signal sequence | |
CN110607319B (en) | Expression vector suitable for bacillus subtilis secretion expression protein and application | |
EP0579360B1 (en) | Hyperthermophiles alpha-amylase gene | |
EP1023438A1 (en) | Expression of starch-binding domain (sbd) | |
EP1187925B1 (en) | Pectate lyase fusion for expression and secretion of polypeptides | |
Freudl | Protein secretion in gram-positive bacteria | |
Lin et al. | Lactose‐induced expression of Bacillus sp. TS‐23 amylase gene in Escherichia coli regulated by a T7 promoter | |
US5294542A (en) | Residual protease-III | |
US6338959B1 (en) | Gene for enzyme having both alkaline pullulanase and alkaline α-amylase activities | |
CN118006535A (en) | Recombinant bacterium for producing high-temperature-resistant high-pressure-resistant prolyl peptidase as well as preparation method and application thereof | |
Heinrich et al. | Expression in Escherichia coli and structure of the gene encoding 4-α-glucanotransferase from Thermotoga maritima. Classification of maltodextrin glycosyltransferases into two distantly related enzyme subfamilies | |
Park et al. | Characterization of the ${\beta}-Cyclodextrin $ Glucanotransferase Bacillus firmus var. alkalophilus and Its Expression in E. coli | |
Wardhan et al. | Molecular analysis of the recA gene of Agrobacterium tumefaciens C58 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1998945082 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1998945082 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998945082 Country of ref document: EP |